Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) have earned an average recommendation of “Moderate Buy ...

Bank of New York Mellon Corp lowered its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 0.5% during the 4th quarter, according to the company in its most recent Form 13F ...

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Rhythm Pharmaceuticals (RYTM – Research Report) today and set a price target of ...

Morgan Stanley analyst Michael Ulz assumed coverage of Rhythm Pharmaceuticals (RYTM) with an Overweight rating and $72 price target The firm ...

10 analysts have shared their evaluations of Rhythm Pharmaceuticals RYTM during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a condensed ...

Given this risk, we thought we'd take a look at whether Rhythm Pharmaceuticals (NASDAQ:RYTM) shareholders should be worried about its cash burn. In this article, we define cash burn as its annual ...

Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.70 per share a year ago.

Rhythm Pharmaceuticals' 01/2025 presentation and Q4 2024 preliminary results press release highlight growing financial performance and promising pipeline developments. Investment thesis focuses on ...

In the last three months, 7 analysts have published ratings on Rhythm Pharmaceuticals (NASDAQ:RYTM), offering a diverse range of perspectives from bullish to bearish. The following table ...

Baker Brothers' 13F portfolio value decreased from $9.65B to $9.36B. Check out the portfolio's top holdings and notable stake ...